NASDAQ:PRFX PainReform (PRFX) Stock Price, News & Analysis $0.89 +0.01 (+0.98%) Closing price 03:59 PM EasternExtended Trading$0.91 +0.02 (+2.35%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsSEC Filings About PainReform Stock (NASDAQ:PRFX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PainReform alerts:Sign Up Key Stats Today's Range$0.88▼$0.9350-Day Range$0.86▼$1.2052-Week Range$0.85▼$7.95Volume35,616 shsAverage Volume1.25 million shsMarket Capitalization$776.02 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview PainReform Ltd. (NASDAQ: PRFX) is a clinical-stage specialty pharmaceutical company focused on developing therapies for the management of acute postoperative pain. The company’s approach is designed to provide prolonged local pain relief while potentially reducing reliance on opioid medications after surgery. PainReform’s lead product candidate, PRF-110, is an investigational extended-release formulation of ropivacaine, a local anesthetic. The product is designed to be administered at the surgical site and gradually release the anesthetic over an extended period, with the goal of providing sustained pain control during the early recovery period following surgery. Founded in Israel, PainReform has pursued the clinical development of its product candidates for potential use in postoperative pain management markets, including the United States and other international markets. PRF-110 remains subject to clinical evaluation and regulatory review, and its availability and commercial use depend on receiving applicable approvals.AI Generated. May Contain Errors. Read More PainReform Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScorePRFX MarketRank™: PainReform scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingPainReform has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePainReform has only been the subject of 1 research reports in the past 90 days.Read more about PainReform's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of PainReform is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PainReform is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPainReform has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.02% of the float of PainReform has been sold short.Short Interest Ratio / Days to CoverPainReform has a short interest ratio ("days to cover") of 0.64, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PainReform has recently increased by 45.77%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPainReform does not currently pay a dividend.Dividend GrowthPainReform does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for PainReform this week, compared to 1 article on an average week. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PainReform insiders have not sold or bought any company stock.Percentage Held by Insiders34.40% of the stock of PainReform is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions37.28% of the stock of PainReform is held by institutions.Read more about PainReform's insider trading history. Receive PRFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRFX Stock News HeadlinesPainReform (NASDAQ:PRFX) Stock Price Down 3.9% - Time to Sell?October 6 at 1:41 AM | americanbankingnews.comPRF Technologies' GridFeed(TM) to Explore Strategic Growth Opportunity in AI Data Center Power OptimizationSeptember 16, 2026 | globenewswire.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 6 at 1:00 AM | Porter & Company (Ad)PRF Technologies to Establish GridFeed™ as a Standalone Subsidiary to Pursue Strategic Alliances for Its AI-Driven Renewable Energy Trading PlatformSeptember 9, 2026 | globenewswire.comPRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy BusinessSeptember 3, 2026 | globenewswire.comPRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy PlatformsJuly 27, 2026 | globenewswire.comPRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026July 21, 2026 | globenewswire.comPRF Technologies Expands DeepSolar Predict™ Platform with Battery-to-Revenue Intelligence, Extending AI-Driven Revenue Optimization Across Solar and Energy Storage AssetsJuly 15, 2026 | globenewswire.comSee More Headlines PRFX Stock Analysis - Frequently Asked Questions How have PRFX shares performed this year? PainReform's stock was trading at $3.2090 at the beginning of 2026. Since then, PRFX shares have decreased by 72.2% and is now trading at $0.8930. How were PainReform's earnings last quarter? PainReform Ltd. (NASDAQ:PRFX) released its quarterly earnings results on Thursday, September, 3rd. The company reported ($1.13) earnings per share (EPS) for the quarter. The company had revenue of $0.01 million for the quarter. When did PainReform's stock split? PainReform shares reverse split on the morning of Thursday, November 21st 2024.The 1-4 reverse split was announced on Monday, November 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. When did PainReform IPO? PainReform (PRFX) raised $23 million in an initial public offering (IPO) on Tuesday, September 1st 2020. The company issued 2,550,000 shares at $8.00-$10.00 per share. Maxim Group and Joseph Gunnar acted as the underwriters for the IPO. How do I buy shares of PainReform? Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PainReform own? Based on aggregate information from My MarketBeat watchlists, some other companies that PainReform investors own include Predictive Oncology (POAI), Bank of America (BAC), Ford Motor (F), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Zomedica (ZOM). Company Calendar Last Earnings9/03/2026Today10/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PRFX's financial health is in the Yellow zone, according to TradeSmith. PRFX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PRFX CIK1801834 Webwww.painreform.com Phone972-3717-7051FaxN/AEmployees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.07 Quick RatioN/A Sales & Book Value Annual Sales$31 thousand Price / Sales25.03 Cash FlowN/A Price / Cash FlowN/A Book Value$23.07 per share Price / Book0.04Miscellaneous Outstanding Shares869,000Free Float570,000Market Cap$776.02 thousand OptionableNot Optionable Beta1.08 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:PRFX) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
